Coherus Biosciences | CHRS - Operating Profit


Coherus Biosciences reported $-45.43M in Operating Profit for its fiscal quarter ending in March of 2025.





Operating Profit Change Date
AbbVie USD 5.81B 1.23B Dec/2025
Acadia Pharmaceuticals USD 17.39M 18.36M Dec/2025
Akebia Therapeutics USD 13.51M 27.82M Mar/2025
ALKERMES USD -10.95M 100.03M Dec/2025
Alnylam Pharmaceuticals USD 29.4M 59.36M Dec/2025
Amarin USD -1.7M 8.47M Sep/2025
Amgen USD 3.96B 464M Dec/2025
Baxter International USD -214.2M 415.4M Dec/2025
Biogen USD 659.6M 192.2M Sep/2025
BioMarin Pharmaceutical USD 198.39M 230.08M Dec/2025
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Coherus Biosciences USD -45.43M 3.13M Mar/2025
Eli Lilly USD 8.99B 599.9M Dec/2025
Fujifilm JPY 89.96B 6.77B Dec/2025
Gilead Sciences USD 2.96B 551M Dec/2025
Ironwood Pharmaceuticals USD 33.22M 7.58M Dec/2024
Merck USD 6.24B 318M Dec/2025
Myriad Genetics USD -23.3M 10.8M Sep/2025
Pacira USD 3.19M 9.96M Dec/2025
Perrigo USD 84.4M 9M Dec/2025
Pfizer USD 4.65B 3.99B Dec/2025
PTC Therapeutics USD -81.62M 85.11M Dec/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Sarepta Therapeutics USD -410.08M 347.2M Dec/2025
Teva Pharmaceutical Industries USD 487M 581M Dec/2025
Vertex Pharmaceuticals USD 1.26B 24.5M Dec/2025
Xencor USD -53.63M 6.11M Dec/2025
Zoetis USD 835M 101M Dec/2025